10 September 2020
Pfizer and BioNTech have reported positive preliminary preclinical data of their lead Covid-19 vaccine candidate, BNT162b2, in mouse and non-human primate models. In a non-human primate preclinical study, BNT162b2 was able to protect rhesus macaques against Covid-19. The vaccine candidate triggered SARS-CoV-2 neutralising antibodies in vaccinated-macaques, along with viral antigen-specific CD4+ and CD8+ T cells.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Russian Direct Investment Fund (RDIF) has teamed up with pharmaceutical company Landsteiner Scientific to supply 32 million doses of the Russian Sputnik V vaccine to Mexico. Deliveries are set to begin in November 2020, subject to Mexican regulatory approvals.
China-based Sinovac Biotech has reported positive data from healthy adults aged 60 and above in Phase I/II clinical trials of its inactivated Covid-19 vaccine candidate, CoronaVac. According to the results, the vaccine showed good safety and immunogenicity, which was comparable to that observed in healthy adults aged 18 to 5 in the prior studies. Sinovac noted that CoronaVac appeared to be well tolerated across low dose, medium dose and high dose groups. Investigators did not report any vaccine-related serious adverse event.
Dasa has signed a letter of intent with United Biomedical subsidiary COVAXX to jointly conduct a large-scale human efficacy clinical trial of the latter’s Covid-19 vaccine candidate in Brazil. COVAXX will provide Dasa with its experimental s UB-612 vaccine for a Phase II/III clinical trial in Brazil. UB-612 is a synthetic multitope peptide-based Covid-19 vaccine candidate.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
